Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer

NCT: NCT05889390 · ACTIVE_NOT_RECRUITING

NCT IDNCT05889390
StatusACTIVE_NOT_RECRUITING
Start Date2023-02-20
Completion2026-12-31

Brief Summary

The aim of this study is to investigate whether the application of concomitant modulated electro-hyperthermia in a neoadjuvant chemotherapeutic setting is beneficial for patients with HER2-negative, stage II-III breast cancer.

Frequently Asked Questions

What is Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer?

Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer is a clinical trial registered under NCT05889390. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05889390?

The current status of NCT05889390 (Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer) is: ACTIVE_NOT_RECRUITING.

When did Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer start?

Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer started on 2023-02-20.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑